Also trades as: 0K16.L (LSE) · $vol 0M
EOLS NASDAQ
Evolus, Inc.
1W: +11.3%
1M: -13.6%
3M: +16.6%
YTD: -8.0%
1Y: -36.0%
3Y: -15.2%
5Y: -41.6%
$6.22
+0.04 (+0.65%)
Weekly Expected Move ±6.0%
$5
$6
$6
$6
$7
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$409.6M
52W Range3.86-9.42
Volume599,630
Avg Volume834,242
Beta1.32
Dividend—
Analyst Ratings
Company Info
CEODavid Moatazedi
Employees350
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
IPO Date2018-02-08
Websiteevolus.com
520 Newport Center Drive
Newport Beach, CA 92660
US
Newport Beach, CA 92660
US
949 284 4555
About Evolus, Inc.
Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc. maintains its corporate headquarters in Newport Beach, California.
Latest News
Jushi Holdings Inc. (JUSHF) Reports Q2 Loss, Tops Revenue Estimates
ResMed (RMD) Soars 4.2%: Is Further Upside Left in the Stock?
Evolus reiterates 2026 net revenue of $327M-$337M while targeting a low to mid-single-digit adjusted EBITDA margin
Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates
Evolus (EOLS) Q1 2026 Earnings Transcript
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Avelar Rui | S-Sale | 3,119 | $4.75 | 2026-03-20 |
| MOATAZEDI DAVID | S-Sale | 13,669 | $4.75 | 2026-03-20 |
| MOATAZEDI DAVID | S-Sale | 116,720 | $4.89 | 2026-03-17 |
| Avelar Rui | S-Sale | 29,996 | $4.89 | 2026-03-17 |
| MOATAZEDI DAVID | M-Exempt | 67,489 | — | 2026-03-16 |